NCT04415944 2026-03-19
HIPEC
Wake Forest University Health Sciences
Phase 2 Completed
Clinical Trials
10 trialsNCT04539327 2026-03-18
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Grupo Español de Investigación en Cáncer de Ovario
Completed
NCT05198804 2026-03-18
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1/2 Completed
NCT00086567 2026-03-09
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
National Institutes of Health Clinical Center (CC)
Completed
NCT06184867 2026-03-06
CATALYST
Rutgers, The State University of New Jersey
Phase NA Completed
NCT04027868 2026-02-17
GREAT
ARCAGY/ GINECO GROUP
Completed
NCT05041257 2026-01-09
PICCOLO
AbbVie
Phase 2 Completed
NCT06173037 2026-01-07
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT01273168 2025-12-23
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT05483933 2025-12-23
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Phase 1 Completed